An 8-month-old infant in Bengaluru is the first suspected case of Human Metapneumovirus (HMPV). The infant's sample, collected on January 2, showed signs of the virus, though the results have not been independently verified. The baby and family have no recent travel history and showed no major symptoms. HMPV, primarily affecting children, is found in around 0.7% of global flu cases. Karnataka health officials have noted the lack of information on the specific strain. While concerns over HMPV's spread in China arise, India's health department has reassured there is "nothing to be alarmed about."

The Health Ministry has assured citizens that India is ready to manage respiratory illnesses like Human Metapneumovirus (HMPV). It said the situation in China, where cases are rising, is "not unusual." Officials are closely monitoring updates from the WHO. India's health system and surveillance are equipped to handle such cases. A recent drill confirmed the nation’s readiness. Citizens are advised to stay calm, maintain hygiene, and seek medical help if needed. HMPV causes cold-like symptoms but can be severe for children, the elderly, and those with weak immunity. The government is watching developments and will act promptly if required.

In a rare medical case, a 53-year-old German surgeon developed cancer after operating on a patient with a rare tumor. During the procedure, the surgeon accidentally cut his hand, but the wound was disinfected and bandaged. Five months later, a malignant lump appeared at the injury site. Genetic tests revealed it was identical to the patient’s cancer. Experts suggest the surgeon’s body had an ineffective immune response, allowing tumor cells to grow. This unique case highlights potential risks for medical professionals despite stringent precautions. Researchers are studying the immune mechanisms involved to improve understanding and safety protocols.

China has downplayed concerns about rising Human Metapneumovirus (HMPV) cases, attributing them to seasonal factors. Foreign Ministry spokesperson Mao Ning assured safety for tourists, stating that respiratory infections peak in winter. Indian health agencies also urged citizens not to panic, highlighting HMPV as a common virus causing mild cold and flu-like symptoms, primarily in the elderly and infants. Dr. Raman Gangakhedkar emphasized that the virus is not severe unless genetic mutations are reported. Preventive measures like hand hygiene and mask usage are advised. Hospitals are prepared to handle cases, and experts stressed the virus has low mortality rates.

The National Centre for Disease Control (NCDC) has confirmed that India has reported no cases of human metapneumovirus (HMPV), a virus linked to rising respiratory illnesses in China. Dr. Atul Goyal, NCDC Director, stated that HMPV causes cold-like symptoms, mainly in children and the elderly, and advised following basic precautions like avoiding close contact during illness. He reassured that taking regular cold or fever medication suffices. India has not seen a significant rise in respiratory outbreaks this winter, and hospitals are prepared. Meanwhile, China is addressing respiratory diseases and setting protocols for unknown pathogens.

The spread of the human metapneumovirus (HMPV) in northern China is raising alarm across Asia, with rising respiratory illnesses and strained healthcare systems. HMPV primarily affects children and can lead to severe conditions like pneumonia and bronchitis. Despite being known for two decades, no vaccine exists for the virus. Health authorities in neighboring countries, including Hong Kong and Japan, are on high alert. Japan is facing a flu outbreak alongside HMPV concerns, reporting over 700,000 cases. Experts urge strict monitoring and preventive measures like wearing masks and handwashing to limit transmission.

China is reportedly facing an outbreak of human metapneumovirus (HMPV), a respiratory virus similar to Covid-19, affecting mainly children and the elderly. Social media claims suggest overwhelmed hospitals and crematoriums, though no official confirmation has been provided. HMPV symptoms include coughing, fever, and respiratory distress, potentially leading to pneumonia in severe cases. The virus, first identified in 2001, has no specific treatment or vaccine. Prevention measures, such as frequent handwashing and mask usage, are advised. While health authorities in China have yet to declare a state of emergency, rising cases have sparked concern over a potential epidemic.

AIIMS researchers in New Delhi have developed chimeric antigen receptor (CAR) T-cell therapy targeting multiple myeloma, a severe blood cancer. This breakthrough involves genetically modifying a patient’s T cells to identify and destroy cancer cells effectively. Initial animal trials have shown promising results. Prof Mayank Singh of BRAIRCH, AIIMS, noted that this therapy could offer an affordable alternative to expensive FDA-approved treatments unavailable to many Indian patients. Clinical validation is pending, but researchers aim to make the treatment accessible. With India facing rising cancer cases, this innovation could significantly reduce the disease burden.

The Democratic Republic of the Congo’s mysterious "Disease X," which claimed 143 lives since October, has been identified as a severe form of malaria. The illness, primarily affecting women and children, led to 592 reported cases, with a fatality rate of 6.2%. Health officials highlighted the impact of malnutrition in worsening respiratory symptoms. WHO data reveal Congo accounts for 11% of global malaria cases and deaths. While 2.2 billion malaria cases and 12.7 million deaths have been averted globally since 2000, the disease remains a severe threat, particularly in Africa, with 597,000 deaths recorded worldwide in 2023.

Russia has developed an mRNA cancer vaccine, launching in early 2025. The vaccine is personalised, using a patient’s tumour to train the immune system to fight cancer. It treats cancer but does not prevent it. The Russian government will provide it free of charge, though it costs 300,000 rubles per dose. Details about its effectiveness and the types of cancer it treats are still unclear. Cancer cases are rising in Russia, with over 635,000 recorded in 2022. The vaccine aims to improve survival rates and is part of ongoing global efforts to develop personalised cancer treatments.